Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

(A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups A, B, C and D). (c) OS since RECIST PD diagnosis (groups A, B and C).(B) Survival time. Patients with PR or CR for first-line EGFR-TKI. (d) PFS since the start of EGFR-TKI (groups A, B and C). (e) OS since the start of EGFR-TKI (groups A, B, C and D). (f) OS since the diagnosis of RECIST PD (groups A, B and C). CR, complete response; EGFR, epidermal growth factor receptor; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.